BRCA1 and ovarian cancer: To these ends, inhibitors of nuclear PARP enzymes (e.g., PARP-1) have significantly improved clinical outcomes in ovarian cancer, especially in patients with BRCA1/2 gene mutations or additional homologous recombination DNA repair pathway deficiencies.